BASDAI CHANGES IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH ANTI-TUMOUR NECROSIS FACTOR THERAPY

被引：0
|
作者：
Clarke, Laura [1 ,2 ]
Kay, Lesley [1 ,2 ]
机构：
[1] Newcastle Hosp NHS Fdn Trust, Musculoskeletal Unit, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England
来源：
RHEUMATOLOGY | 2010年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I58 / I59
页数：2
相关论文
共 50 条
  • [21] Is it necessary to perform sequential bath ankylosing spondylitis disease activity index (BASDAI) and spinal visual analogue scale (VAS) measurements prior to commencement of anti-tumour necrosis factor (TNF) alpha therapy in ankylosing spondylitis (AS)?
    Tierney, Caroline A.
    Chinoy, Hector
    Chattopadhyay, Chandra
    RHEUMATOLOGY, 2008, 47 : II76 - II76
  • [22] Tuberculosis in patients with ankylosing spondylitis treated with anti tumor necrosis factor
    Kinikli, G.
    Kucuksahin, O.
    Turgay, M.
    Ates, A.
    Kinikli, S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 355 - 355
  • [23] The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
    Laura Watts
    Tugce Karaderi
    Amity Roberts
    Louise Appleton
    Tom Wordsworth
    Carla Cohen
    Paul Wordsworth
    Matteo Vecellio
    Genes & Immunity, 2019, 20 : 167 - 171
  • [24] The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
    Watts, Laura
    Karaderi, Tugce
    Roberts, Amity
    Appleton, Louise
    Wordsworth, Tom
    Cohen, Carla
    Wordsworth, Paul
    Vecellio, Matteo
    GENES AND IMMUNITY, 2019, 20 (02) : 167 - 171
  • [25] ASSESSMENT AND DIAGNOSIS OF ANKYLOSING SPONDYLITIS: TREATMENT OPTIONS FOR PATIENTS BOTH ON AND NOT ON ANTI-TUMOUR NECROSIS FACTOR AT CHESTERFIELD ROYAL HOSPITAL
    Longmore, Belinda A.
    Lawrence, Catherine R.
    RHEUMATOLOGY, 2016, 55 : 118 - 119
  • [26] Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
    Rudwaleit, M
    Listing, J
    Brandt, J
    Braun, J
    Sieper, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (06) : 665 - 670
  • [27] Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging
    Martina Karpitschka
    Patrizia Godau-Kellner
    Herbert Kellner
    Annie Horng
    Daniel Theisen
    Christian Glaser
    Bernhard Brandlhuber
    Maximilian Reiser
    Sabine Weckbach
    European Radiology, 2013, 23 : 1773 - 1784
  • [28] Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging
    Karpitschka, Martina
    Godau-Kellner, Patrizia
    Kellner, Herbert
    Horng, Annie
    Theisen, Daniel
    Glaser, Christian
    Brandlhuber, Bernhard
    Reiser, Maximilian
    Weckbach, Sabine
    EUROPEAN RADIOLOGY, 2013, 23 (07) : 1773 - 1784
  • [29] Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
    Ole R. Madsen
    Anne Rytter
    Lonnie B. Hansen
    Charlotte Suetta
    Charlotte Egsmose
    Clinical Rheumatology, 2010, 29 : 849 - 854
  • [30] Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients
    Madsen, Ole R.
    Rytter, Anne
    Hansen, Lonnie B.
    Suetta, Charlotte
    Egsmose, Charlotte
    CLINICAL RHEUMATOLOGY, 2010, 29 (08) : 849 - 854
12345